FibroGen Inc

Overview

FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF), duchenne muscular dystrophy (DMD); FG-5200 for the treatment of Corneal Blindness. The company is also evaluating pamrevlumab in Phase II for investigating its safety and efficiency in patients with COVID-19. The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.
Key Stats
Address
409 Illinois St, SAN FRANCISCO, California
Headquarters

United States of America

Contact

1 415 9781200

No of Employees

599

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

FGEN [NASD]

Revenue (2020)

$176 m

-31.4% (2020 vs 2019)
Net Income (2020)

$-189 m

-145.6% (2020 vs 2019)
Net Profit Margin

-107 %

-257.9% (2020 vs 2019)
Market Cap *

$1,111 m

EPS *

$-2.1

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters FibroGen IncJohnson & JohnsonF. Hoffmann-La Roche LtdBayer AG
Key Information
Headquarters United States of America United States of America Switzerland Germany
Headquarter City SAN FRANCISCO NEW BRUNSWICK BASEL LEVERKUSEN
Headquarter State/Province California New Jersey - -
No. of Employees 599 134,500 101,465 99,439
Entity Type Public Public Public Public

Products & Services

FibroGen is a biotechnology company that harnesses connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology for the discovery and development of medicines to address the unmet medical needs of anemia, cancer, and fibrotic disease. Key products and of the company include the following:

Products
  • • Approved:
  • • Roxadustat:
  • • Anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients.
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Tricia Stewart Chief People Officer Senior Management 2021 - Ms. Tricia Stewart has been the Chief People Officer of the company since May 2021. Prior to this, she served...
Enrique Conterno Chief Executive Officer; Director Executive Board 2020 53 Mr. Enrique Conterno has been the Chief Executive Officer and a Director of the company since January 2020. Previously, he...
Thane Wettig Chief Commercial Officer Senior Management 2020 - Mr. Thane Wettig serves as Chief Commercial Officer of the company. Prior to this, he served as Chief Commercial Officer...
James A. Schoeneck Chairman Executive Board 2020 62 Mr. James A. Schoeneck has been the Chairman of the company since January 2020. Previously, he served as the Interim...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In June, the company and HiFiBiO entered into a partnership to advance next-generation therapies to…
2021 Regulatory Approval In April, the US FDA granted the company's Pamrevlumab, Fast Track Designation for the treatment…
2021 Regulatory Approval In April, the company received Rare Pediatric Disease Designation from the US FDA for the…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Fibrogen Europe Oy

Address

Viikinkaari 6, Helsinki
Finland

Telephone

358 9 3463424

Website

www.fibrogen.com/europe

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
19 Jul 2021 Eluminex Biosciences Enters into Licensing Agreement with FibroGen Licensing Agreement Eluminex Biosciences Ltd FibroGen Inc
17 Jun 2021 FibroGen Enters into Licensing Agreement with HiFiBiO Licensing Agreement FibroGen Inc HiFiBiO Therapeutics
14 Aug 2017 FibroGen Raises USD374.9 Million in Public Offering of Shares Equity Offering FibroGen Inc
06 Apr 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
29 Feb 2016 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
30 Oct 2014 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

27

Active Jobs

5

Posted

13

Closed

Job Trends

Latest Jobs

Job title Company Country
Vice President, Global Head of Regulatory Affairs FibroGen Inc United States
Director/Senior Director, Biostatistics FibroGen Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar